Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,001–2,100 of 3,116
20.シリングテストに影響を及ぼす検査とその補正法(関東・東京部会(第23回))
森田, 立., 氏家, 盛., 野沢, 武., et al. (1977) · 日本放射線技術學會雜誌
2025 Nutrition Science & Communications Forum: Summary
Steiber, A. L., Paulsen, E., & Brown, N. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156324
Kramer, C. M., Borlaug, B. A., Zile, M. R., & Packer, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.034
Brancato, D., Borretta, G., Chianelli, M., Disoteo, O., Grasso, M., Grimaldi, F., Guastamacchia, E., Muratori, F., Oleandri, S., Orio, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907270
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
Geraci, C., Cannarella, R., Morello, V., Paternò, V., Petrina, S. M., Esposito, R., Geraci, G., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2026) · Cancers · doi:10.3390/cancers18142212
Heart and Brain: Linking Obesity-Related Inflammation, Cardiovascular Disease and Cognitive Function
Reiss, A. B., Gulkarov, S., Syed, U., Ben-Dor, G. A., Srivastava, A., Singh, M., & Leon, J. D. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13100477
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Chan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
“Large clinical trials have demonstrated the beneficial impact GLP-1s on atherosclerotic disease, including lower rates of heart disease and failure, myocardial infarction, and stroke, particularly in patients with diabetes [25,26].”
Zhang, Z., Liu, S., Xian, J., Zhang, Y., Zhang, C., Wang, Z., Deng, H., Feng, J., & Yao, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26154
Impact of Obesity Medications on Gastric Function
Torres, J. A., & Sullivan, S. A. (2026) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161261417564
22 還元進行過程の調査 : 小型高炉による製銑過程に関する基礎研究 I(製銑, 日本鉄鋼協会第 70 回(秋季)講演大会講演論文集 (I))
大蔵, 明., カルデロン, F. P., & 松下, 幸. (1965) · 鐵と鋼 : 日本鐡鋼協會々誌
Kır, Y., Haymana, C., Torus, B., Güler, B. Y., Uflaz, B., Eroğlu, G., Gursoy, A., Boyraz, E., Akkan, T., Akın, Ş., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03024-w
Hat die inkretinbasierte Hypertoniebehandlung eine Zukunft?
Zidek, W. (2026) · CardioVasc · doi:10.1007/s15027-025-3944-5
Lund, N., Lübker, C., Rasche, A., Taylor, M., Xu, W., Taneja, L., Shukla, S., Olivieri, A., & Sharma, Y. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01659-4
GLP-1RA based therapies in the young and old
Rigas, G., Alexander, S., & Haywood, C. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000900
Vignarajah, A., Tan, M. C., Vigneswaramoorthy, N. A., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.01.023
Ferreira, V. M., & Muller, V. A. (2026) · Cureus · doi:10.7759/cureus.110621
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Lixandru, N., Gaiţă, L., Popescu, S. D., Herascu, A., Timar, B., & Timar, R. Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010152
“…similarly to the results of the same SELECT randomized controlled trial and also to the results of several meta-analyses with this class of antihyperglycemic agents, although each was carried out with a completely different design not directly comparable with this real-world sample [26–29].”
InfluentialAlaycı, B., & Gerçek, Ö. Z. (2026) · BMC Endocrine Disorders · doi:10.21203/rs.3.rs-9973131/v1
Kim, D. W., Sheu, E. G., Nimeri, A. A., Cristancho, C., Salim, K., Shin, H., McDonnell, M. E., & Apovian, C. M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08913-w
Jiménez‐Mausbach, M., Tijms, B. M., Paterson, C., & Refsgaard, J. C. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70432 · Cited by 1
Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy
Jordan, M., Stucki-Koch, A., Schinke, M., Willmer, L., Senne, I., Abbas, N., Bentele, M., Oldenkott, D., Lachmann, N., Feldbrügge, L., et al. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02695-5 · Cited by 1
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes
Muskiet, M. H. A., & Apperloo, E. M. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1567-6
Huang, Y., Au, K., Mahawar, K. K., Pan, A., Shabbir, A., Zheng, M., Ghanem, O. M., & Yang, W. (2025) · The Innovation · doi:10.1016/j.xinn.2025.101085
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Implications of the era of incretin-based weight loss therapy in menopause
Palacios, S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2540000 · Cited by 1
Ostrominski, J. W., Plutzky, J., Scirica, B. M., Hovingh, G. K., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Morville, T. H., Quiroga, M., Sofer, Y., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.3566 · Cited by 2
Self-citationInterpreting Real-World Cardiovascular Outcomes With GLP-1 Receptor Agonists
Akbar, U. A., & Balla, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.08.028
Treatment potential of oral small-molecule GLP-1 receptor agonists
Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01135-9
Abdel-Malek, M., Thayabaran, D., & Miras, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00010-3
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“The only available ones are those regarding the positive impact on cardiovascular outcomes of GLP1-RAs [33], that also increase energy expenditure.”
InfluentialAlTaweel, M., Jalbani, A. A., Memon, F., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16090481
“Residual and unmeasured confounding cannot be excluded, particularly confounding by indication in the association between semaglutide exposure and class membership, given semaglutide’s own established, independent effect on cardiovascular risk [24].”
Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide
Tiwari, A., Pahuja, V., Vipin, V. P., Erande, S. G., Indurkar, S. A., Kumar, A., Saha, I., Lahiri, K. D., Kishore, R., Alok, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_21_26
Implications of Medications in Gastrointestinal Motility
Peixoto, A., Araújo, F. D., Maciel, P., Frias, J., & Câmara, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27658-3.00025-1
Strugała, N., Kostrzewski, M., Noworolska, M., Wojtaszkiewicz, D., Skrzeczyna, J., Sapała, E., Bednarska, K., Zurek, J., Wiśniewska, M., Bulenda, M., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6003
“A breakthrough was the SELECT trial, which demonstrated that semaglutide at a dose of 2.4 mg reduces the risk of MACE by 20% in patients with overweight or obesity and established cardiovascular disease, but without coexisting diabetes [12, 17].”
InfluentialIglesias, P. C. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02828-0
Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients
Tyurina, A. V., Kurochkina, N. S., & Владиславович, Е. М. (2026) · Kardiologiia · doi:10.18087/cardio.2026.2.n3116 · Cited by 1
Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications
Medeiros, R. D. O., Galhardi, C. M., Urzagaste, C. H. V., Oliveros, C. M., Pires, G. S., da Silva, V. W. C., de Novaes, F. Q., Suzuki, I. G., dos Reis, H. C., Neto, J. A. P., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14071414
“…glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the most promising pharmacological strategies, demonstrating consistent efficacy in promoting weight reduction, improving glycemic control, and reducing cardiovascular risk in individuals with overweight or obesity [27,28].”
Brady, A., Roopnarinesingh, R. C., Craig, R., & Bampoe, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9197869/v1
Kang, X., Liang, X., Cui, W., Song, Y., Wang, X., Hai, X., Wu, P., Hao, Y., Ma, X., & Yan, N. (2026) · Research Square · doi:10.21203/rs.3.rs-10330033/v1
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
“Cardiovascular bene fi t in people with overweight or obesity is supported by SELECT (108), but gastrointestinal adverse effects, gallbladder disease, cost, and persistence remain important.”
Incretin-Based Therapies and Cardiovascular Outcomes: Beyond Weight Loss
Després, J., & Neeland, I. J. (2026) · Circulation · doi:10.1161/circulationaha.126.079488
Semaglutide-associated Twiddler syndrome
Seiler, T., Noti, F., Laimer, M., et al. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag103
“Even in nondiabetic patients with cardiovascular disease, these effects reduce cardiovascular mortality, myocardial infarctions, and strokes [ 1].”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“%) in adults with ASCVD and obesity/overweight without diabetes at 156 weeks [12].”
InfluentialGreiner, T. U., Seeley, R. J., & Bäckhed, F. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00158.2025
Role of Obesity-Triggered Inflammation in Aging
Fülöp, T., Franck, M., Cohen, A. A., Alami, M., Berrougui, H., Khalil, A., Pawelec, G., & Witkowski, J. M. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_8
Qazi, S. U., Ansari, H. U. H., Tharwani, Z. H., Altaf, Z., Noman, A., Ghazanfar, S., Kumar, S., Ansari, H. W., Nasir, M. M., & Qazi, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01409-3 · Cited by 1
Gragnano, F., Bøg, M., Bojesen, A. B., et al. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01649-6
Self-citationOrozco, R., Romero, P., & Palacios, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02166-4
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2610-3294
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Altés, A., Moreno, Ó., Sastre-Belío, M., Rodríguez-Urgellés, E., Pérez-Alcántara, F., Larsen, S., Martín‐Lorenzo, A., Sandín, M., & Vidal, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03644-x
“…mg is the only obesity drug with evidence of reduced risk of cardiovascular (CV) death, all‑cause mortality, stroke and myocardial infarction (MI) [48], and has shown improvement in complications such as HF with preserved ejection fraction, prediabe‑ tes, osteoarthritis and metabolic…”
InfluentialOltre il controllo metabolico: GLP1-RA e riduzione del rischio di tumori legati all’obesità
Botta, M., & Perseghin, G. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01761-x
“Nei pazienti con obesità è stato dimostrato, inoltre, che il loro impiego riduce il rischio di eventi cardiovascolari [2] e contribuisce alla risoluzione della steatoepatite non al-colica [3].”
Immunosenescence in Cardiovascular-Kidney-Metabolic Syndrome: A Unifying Mechanistic Framework
Sano, M. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0060
Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists
Harrington, J., McGuire, D. K., & Inzucchi, S. E. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.013
Zhang, Z.-W., Li, R., Zhang, L., Ma, Z.-F., Wang, H.-Y., & Cui, Q. (2025) · Food and Bioproducts Processing · doi:10.1016/j.fbp.2025.06.006
Kugathasan, L., Tsoukas, M. A., Nardone, M., Sridhar, V. S., Muskiet, M. H. A., Cherney, D. Z. I., Haidar, A., & Pasqua, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70525
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 3
“Lowering atherogenic lipoproteins causally reduces ASCVD risk, providing a meaningful, weight-independent benefit on extrahepatic outcomes that complements hepatic histology [22-23].”
Alkasabrah, O. Y., Elzayat, M., Chaudhry, M. Q., Eldesouki, M. H., Ibrahim, S., Serhan, A., & Sharma, T. (2026) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2026.2724644
Jin, C., Huang, L., Wei, Y.-Y., Xu, Y.-S., Zhang, B., Wu, J., & Fan, L.-L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05958-8 · Cited by 1
“First, weight loss induced by semaglutide may reduce cardiac load, improve insulin resistance, and alleviate chronic inflammation, potentially contributing to plaque stability and fewer revascularization events [7].”
InfluentialLeading the Charge in Obesity Management: A Call to Action for Cardiovascular Nursing
Bryant, E., Laing, K., Langdon, K. D., Salisbury, H., & Villavaso, C. D. (2025) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001192
Schifano, F., Luca, M. A. D., Bonaccorso, S., Arillotta, D., Floresta, G., Martinotti, G., Papanti, G. D., Corkery, J., Chiappini, S., & Guirguis, A. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01709-w · Cited by 1
Craig, C. M., Tan, M. J., Shamloo, T., Perelman, D., & McLaughlin, T. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156773
Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Zindani, S., Mevawalla, A., Sarfraz, A., Mumtaz, K., & Pawlik, T. M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10300-1 · Cited by 1
“24 In turn, these medications may preferentially improve liver outcomes among patients with underlying liver conditions such as metabolic-associated steatohepatitis or alcohol associated liver disease.”
Cardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review
Enache, V., Popescu, D.-C., Marcu, B., Diaconu, M., & Nechita, A. C. (2026) · Medicina · doi:10.3390/medicina62091742
“Its cardiovascular benefits have been demonstrated in dedicated outcome trials conducted in other clinical populations and should not be interpreted as evidence of a direct cardiovascular effect mediated by improvement in MASH [108,111].”
Umińska, J. M., Ratajczak, J. M., Niezgoda, P., Gajda, R., Szarpak, Ł., Kubica, J., & Navarese, E. P. (2026) · Obesities · doi:10.3390/obesities6030038 · Cited by 3
“In SELECT, semaglu-tide 2.4 mg reduced major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes [15].”
InfluentialCoelho, G. S., Sales, G. M., Bezerra, A. F., Santos, G. C., & Silva, T. G. E. (2024) · Revista Contemporânea · doi:10.56083/rcv4n7-040
Zhou, Q., & Shen, Y. (2026) · Clinical Proteomics · doi:10.1186/s12014-026-09583-7
“Representative advances include glucagon-like peptide-1 (GLP-1) receptor agonists and newer multi-receptor co-agonist peptides, which show clinical value for weight management and for cardiore-nal outcomes [138–141].”
Elsayed, A., Ayoub, W. J., ELSAYED, N., Stephens, J. P., Udongwo, N., Elsayed, Y. A.-E., & Ghali, J. K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00322-3
“The SELECT trial (November 2023) enrolled 17,604 patients with overweight or obesity (BMI ≥ 27 kg/m²) and established ASCVD but without diabetes [4].”
Hu, Y., Zheng, L., & Zhang, Y. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3419
Chaturvedi, S., Turan, T. N., Voeks, J. H., Lopes-Virella, M. F., Goldstein, J., Teal, P. A., Foster, M. T., Howard, V. J., Meschia, J. F., Lal, B. K., et al. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.108025
Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives
Maggio, E., Trivigno, S., Mariani, M. V., Piro, A., Pierucci, N., Vernile, A., Vinciullo, S., Palombi, M., Vizza, C. D., & Lavalle, C. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100506
Cardiovascular Effects of GLP-1 Analogues
Amoresano, L. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_15
Research progress in precision medicine for type 2 diabetes based on the GLP-1
Wang, S., Yuan, C., Wang, H., Ye, X., Ruan, S., Yi, L., Yang, W., Wang, Z., Wang, N., Li, J., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1721842 · Cited by 2
“The SELECT and FLOW trials have demonstrated that GLP-1R agonists can signi fi cantly reduce the risk of cardiovascular and renal diseases in the studied populations (8, 9).”
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part I
Cowley, A., Dattani, A., Brady, E. M., McCann, G. P., & Gulsin, G. S. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.441
The Cost-Effectiveness Evolution of Cardiovascular Care
Fonarow, G. C., Navar, A. M., & Yancy, C. W. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5240
Garvey, W. T., Ard, J. D., Connery, L. E., Frías, J. P., le Roux, C. W., Pietiläinen, K. H., DINESEN, M., Hagen, B. F., Larsen, L., Hesse, D., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00213-5 · Cited by 2
Zhu, D. T., Gao, C., Kwon, Y. I. C., & Lai, A. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10658-2
How diet therapy affects obesity-associated depressive symptoms: from mechanism to therapeutics
Wang, R., Chen, Z., Wang, Y., Zhang, Y., & Song, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1846186
“…and semaglutide, may cause adverse reactions such as gastrointestinal dysfunction and pancreatitis, while commonly used antidepressants such as paroxetine and escitalopram can lead to metabolic disorders and some neuropsychiatric symptoms (Cao et al., 2024; Lincoff et al., 2023; Son and Kim, 2020).”
Siddiqi, T. J., Khan, M. M., Fonarow, G. C., Butler, J., & Greene, S. J. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf004
Obesity and Cardiovascular Diseases: CVIA State-of-the-Art Review
Liu, N., Pan, Y., Liu, F., Mei, J., Zhang, X., Zhang, R., Zhang, S., Luo, F., Wu, Y., Gong, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0010 · Cited by 1
Lahooti, A., Aneke-Nash, C. S., Johnson, K. E., Rizvi, A., Baig, M. U., Shukla, A. P., Newberry, C. A., Smith, E., Sharaiha, J. M., Hanscom, M. H., et al. (2025) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2025.250942
Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Nadal, C., & Masmiquel, L. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106941
Pedicino, D., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf236
Brandts, J. (2026) · CardioVasc · doi:10.1007/s15027-026-4016-1
“…dieser eng verwobenen Pathophysiologien zu über‑ winden und eine ganzheitliche Präventi‑ onsstrategie über den gesamten Lebens‑ verlauf zu etablieren [13], verbes‑ serten in der STEP‑ HFpEF‑ Studie die Symptome der Herzinsuffizienz [14] und zeigten in Phase‑2‑Studien eine MASH‑Resolution [15].”
Carlson, K., Kaur, J., Gaber, C. E., Reutrakul, S., & Kim, K. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2726017
Alternative Perspectives on Obesity and Hypertension
Schulhof, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000802
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
Writing Task Force iCARDIO-Alliance (2025) · Global Cardiology · doi:10.4081/cardio.2025.71 · Cited by 1
Lalani, I., Nambayan, R., Carbonell, C., Ruan, Y., O'Sullivan, D. E., Stukalin, I., Hilsden, R. J., & Brenner, D. R. (2026) · Cancer Control · doi:10.1177/10732748261483767 · Cited by 1
“Existing large GLP-1RA trials designed for CVD mortality reduction such as the EXCEL trial, 108 may have sufficient sample size for direct GLP-1RA and cancer evidence as the target population had considerable overlap for adults at increased risk for OAC and other cancers.”
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
Black-market weight loss injectables in Hidradenitis Suppurativa: a single-centre survey
Drayne, R., Kirby, B., & Hughes, R. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04586-7
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Chaparala, P., Rongali, D. A., Khot, M., Rangachari, B., Ahmed, K. U., Suri, S., Greeshma, M., & Shafiq, M. M. (2026) · Cureus · doi:10.7759/cureus.109350
Sami, N., Parikh, M. A., Mihatov, N., Schwartzman, M. L., Frishman, W. H., & Peterson, S. J. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001345
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
